logo
logo

Kinnate Biopharma Closes $98 Million Series C Financing

Aug 26, 2020almost 5 years ago

Amount Raised

$98 Million

Round Type

series c

San Diego

Description

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced that it has raised $98 million in a Series C financing. The financing was led by RA Capital Management with participation from additional new investors: Viking Global Investors; Venrock Healthcare Capital Partners; Fidelity Management & Research Company, LLC; Janus Henderson Investors; Surveyor Capital (a Citadel company); Boxer Capital of Tavistock Group; Logos Capital; and an investment fund associated with SVB Leerink. Existing investors Foresite Capital, OrbiMed, Nextech Invest, and Vida Ventures also participated in the round. In December 2019, Kinnate closed a $74.5 million Series B financing.

Company Information

Company

Kinnate Biopharma

Location

San Diego, California, United States

About

Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which we refer to as our Kinnate Discovery Engine, to develop targeted therapies. Headquartered in San Diego, the Kinnate team is composed of drug discovery experts supported by world-class scientific advisors and investors. For more information, please visit www.kinnate.com and follow us on LinkedIn.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech